Stefan Pusch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4027132/publications.pdf

Version: 2024-02-01

79	5,710	117453	82410
papers	citations	34 h-index	72 g-index

81	81	81	9043
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Brain tumour cells interconnect to a functional and resistant network. Nature, 2015, 528, 93-98.	13.7	787
2	A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327.	13.7	613
3	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathologica, 2011, 122, 11-19.	3.9	445
4	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine, 2018, 24, 1192-1203.	15.2	359
5	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathologica, 2013, 125, 651-658.	3.9	324
6	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathologica, 2013, 125, 351-358.	3.9	208
7	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathologica, 2012, 123, 223-233.	3.9	204
8	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 409-414.	3.3	152
9	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 2017, 133, 629-644.	3.9	146
10	CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathologica, 2012, 123, 853-860.	3.9	130
11	The Arabidopsis thaliana F-Box Protein FBL17 Is Essential for Progression through the Second Mitosis during Pollen Development. PLoS ONE, 2009, 4, e4780.	1.1	124
12	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nature Cancer, 2021, 2, 723-740.	5.7	110
13	Control of Cell Proliferation, Organ Growth, and DNA Damage Response Operate Independently of Dephosphorylation of the Arabidopsis Cdk1 Homolog CDKA;1 Â. Plant Cell, 2009, 21, 3641-3654.	3.1	106
14	A General G1/S-Phase Cell-Cycle Control Module in the Flowering Plant Arabidopsis thaliana. PLoS Genetics, 2012, 8, e1002847.	1.5	103
15	IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Research, 2016, 76, 7118-7129.	0.4	99
16	T-Loop Phosphorylation of Arabidopsis CDKA;1 Is Required for Its Function and Can Be Partially Substituted by an Aspartate Residue. Plant Cell, 2007, 19, 972-985.	3.1	98
17	Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia, 2017, 31, 2020-2028.	3.3	97
18	Analysis of the Subcellular Localization, Function, and Proteolytic Control of the Arabidopsis Cyclin-Dependent Kinase Inhibitor ICK1/KRP1. Plant Physiology, 2006, 141, 1293-1305.	2.3	96

#	Article	IF	Citations
19	A Photochemical One-Pot Three-Component Synthesis of Tetrasubstituted Imidazoles. Organic Letters, 2014, 16, 5430-5433.	2.4	73
20	D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Acta Neuropathologica Communications, 2014, 2, 19.	2.4	72
21	G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling. Cell, 2021, 184, 655-674.e27.	13.5	65
22	CIC protein instability contributes to tumorigenesis in glioblastoma. Nature Communications, 2019, 10, 661.	5.8	63
23	Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1416-1425.	2.2	62
24	PCRâ€•and Restriction Endonuclease‐Based Detection of IDH1 Mutations. Brain Pathology, 2010, 20, 298-300.	2.1	58
25	Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate. Acta Neuropathologica, 2012, 124, 883-891.	3.9	58
26	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. Clinical Cancer Research, 2019, 25, 1851-1866.	3.2	55
27	Scientific correspondence. Neuropathology and Applied Neurobiology, 2011, 37, 428-430.	1.8	54
28	Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and Î±-KG. Acta Neuropathologica Communications, 2013, 1, 18.	2.4	54
29	Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia, 2015, 63, 78-90.	2.5	51
30	Detection of 2â€‐Hydroxyglutarate in Formalin‐Fixed Paraffin‐Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry. Brain Pathology, 2012, 22, 26-31.	2.1	49
31	A Photoinduced Cobalt-Catalyzed Synthesis of Pyrroles through in Situ-Generated Acylazirines. Journal of Organic Chemistry, 2016, 81, 4170-4178.	1.7	46
32	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. Acta Neuropathologica, 2019, 137, 837-846.	3.9	43
33	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. Clinical Cancer Research, 2019, 25, 253-265.	3.2	42
34	Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. Cancer, 2014, 120, 2440-2447.	2.0	39
35	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. Journal of Clinical Investigation, 2015, 125, 593-606.	3.9	35
36	Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma. International Journal of Molecular Sciences, 2018, 19, 2903.	1.8	30

#	Article	IF	Citations
37	Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukinâ€6 signaling in hepatocellular carcinoma. Hepatology, 2016, 64, 828-842.	3.6	29
38	Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p. Scientific Reports, 2019, 9, 4796.	1.6	29
39	Karyopherin Î±2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer. Cell Communication and Signaling, 2019, 17, 159.	2.7	29
40	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathologica Communications, 2018, 6, 21.	2.4	28
41	Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E. Cancer Research, 2019, 79, 4994-5007.	0.4	28
42	NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis. Oncogene, 2020, 39, 3128-3144.	2.6	28
43	Identification of kinase substrates by bimolecular complementation assays. Plant Journal, 2012, 70, 348-356.	2.8	25
44	NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. Journal of the National Cancer Institute, 2022, 114, 579-591.	3.0	25
45	Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. Leukemia, 2016, 30, 782-788.	3.3	23
46	Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. Journal of Medicinal Chemistry, 2018, 61, 8981-9003.	2.9	23
47	Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. Neuro-Oncology, 2023, 25, 263-276.	0.6	23
48	Bimolecular-Fluorescence Complementation Assay to Monitor Kinaseâ€“Substrate Interactions In Vivo. Methods in Molecular Biology, 2011, 779, 245-257.	0.4	20
49	NDRG1 prognosticates the natural course of disease in WHO grade II glioma. Journal of Neuro-Oncology, 2014, 117, 25-32.	1.4	19
50	Absolute configuration of the synthetic cannabinoid MDMB-CHMICA with its chemical characteristics in illegal products. Forensic Toxicology, 2016, 34, 344-352.	1.4	18
51	Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation. Journal of Neuro-Oncology, 2020, 147, 1-14.	1.4	18
52	Prohibitin, STAT3 and SH2D4A physically and functionally interact in tumor cell mitochondria. Cell Death and Disease, 2020, 11, 1023.	2.7	17
53	Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents. Cells, 2020, 9, 1389.	1.8	17
54	Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 388-393.	1.0	15

#	Article	IF	Citations
55	Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening. RSC Advances, 2016, 6, 96735-96742.	1.7	13
56	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells. Molecular Cancer Therapeutics, 2020, 19, 1736-1750.	1.9	13
57	cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. Journal of Neuro-Oncology, 2020, 146, 9-23.	1.4	12
58	Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. Scientific Reports, 2016, 6, 30486.	1.6	11
59	T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas. Clinical Cancer Research, 2022, 28, 378-389.	3.2	11
60	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma. Cancers, 2022, 14, 1154.	1.7	11
61	Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. Neuropathology and Applied Neurobiology, 2011, 37, 330-332.	1.8	10
62	Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. Bioorganic and Medicinal Chemistry, 2017, 25, 6379-6387.	1.4	10
63	Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation. International Journal of Cancer, 2019, 145, 461-473.	2.3	9
64	The Multifunctional Role of EMP3 in the Regulation of Membrane Receptors Associated with IDH-Wild-Type Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 5261.	1.8	7
65	Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. Blood, 2016, 128, 745-745.	0.6	7
66	Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique. Frontiers in Oncology, 2016, 6, 46.	1.3	6
67	RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. Acta Neuropathologica, 2019, 138, 275-293.	3.9	6
68	Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas. International Journal of Cancer, 2022, 151, 1431-1446.	2.3	6
69	AAMP is a binding partner of costimulatory human B7-H3. Neuro-Oncology Advances, 2022, 4, .	0.4	4
70	An activating germline IDH1 variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid. Human Genetics and Genomics Advances, 2020, 1, 100006.	1.0	3
71	mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation. Cell Stress, 2017, 1, 55-67.	1.4	3
72	Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening. Letters in Drug Design and Discovery, 2019, 16, 861-867.	0.4	2

#	Article	IF	Citations
73	OS10.2 R-2-Hydroxyglutarate shapes the immune microenvironment in IDH1-mutant gliomas. Neuro-Oncology, 2017, 19, iii20-iii21.	0.6	0
74	P04.62 The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling. Neuro-Oncology, 2018, 20, iii293-iii294.	0.6	0
75	LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2021, 23, i33-i34.	0.6	0
76	OS12.4.A MHC class II-restricted transgenic T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas. Neuro-Oncology, 2021, 23, ii15-ii15.	0.6	0
77	Deciphering the role of FHL1 as tumor suppressor in gallbladder cancer. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.2	0
78	LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. Neuro-Oncology, 2022, 24, i91-i91.	0.6	0
79	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. Neuro-Oncology, 2022, 24, i91-i92.	0.6	0